Abstract:BACKGROUND: The value of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in neoadjuvant systemic therapy for breast cancer remains uncertain.METHODS: Both electronic databases and proceedings of oncologic meetings were included in systematic literature search. Pooled rates of pathological complete response (pCR), odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-effect or random-effect model to determine the effect of neoadjuvant nab-paclitaxel.RESULTS: Twenty-one studies with 2357 patients were included, 3 of which were randomized clinical trials. The aggregate pCR(ypT0/is ypN0) rate was 32% (95% CI 25-38%) in unselected breast cancer patients and variated in different subtypes. Within randomized clinical trials, the probability of achieving pCR was significantly higher in the nab-paclitaxel group than in the conventional taxanes group (OR = 1.383, 95%CI 1.141-1.676, p = 0.001). For non-hematological toxic effect, any grade and grade 3-4 peripheral sensory neuropathy occurred more frequently with nab-paclitaxel compared to paclitaxel (any grade, OR = 2.090, 95%CI 1.016-4.302, p = 0.045; grade3-4, OR = 3.766, 95%CI 2.324-6.100, p < 0.001). Hypersensitivity was more common with paclitaxel than nab-paclitaxel at any grade and grade 3-4.CONCLUSION: nab-paclitaxel is an effective cytotoxic drug in neoadjuvant treatment of breast cancer, especially for aggressive tumors in terms of pCR. Exchange of nab-paclitaxel for conventional taxanes could significantly improve pCR rate with reasonable toxicities.

Progress in research of antineoplastic taxane

Research Progress in Chemoresistance Mechanism of Paclitaxel and the Future Direction

Research Advances in Clinical Applications, Anticancer Mechanism, Total Chemical Synthesis, Semi-Synthesis and Biosynthesis of Paclitaxel

Research progress on nanoparticle albumin-bound paclitaxel

Exploration and Outlook of Recent Applications of Paclitaxel in Breast Cancer Treatment

Progress in the Study of Taxanes Against Multi-Drug Resistant Tumor

Progress of clinical research and new formulations of paclitaxel

Progress on the Prodrugs of Paclitaxel

Research Progress of Paclitaxel Drug Source Solution and Extraction and Separation Technology

Recent progress in nanoformulations of cabazitaxel

Progress of Clinical Research on New Nano-Drug Delivery System of Paclitaxel

Research progress of paclitaxel drug delivery systems

Probing the new strategy for the oral formulations of taxanes: changing the method with the situation

Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer

Paclitaxel (Taxol®): A new natural product with major anticancer activity

Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy

Research Development on Drug-Resistance Mechanism of Taxanes

Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis

Research status of anti-tumor targted drugs

Recent Progress of Paclitaxel Delivery Systems: Covalent and Noncovalent Approaches

Recent Research Progress in Taxol Biosynthetic Pathway and Acylation Reactions Mediated by Taxus Acyltransferases